NICE say NO to dasatinib and high dose IM. Full Guidance
Guidance: Patient version
Dasatinib, high-dose imatinib and nilotinib for chronic myeloid leukaemia:
This document is about when dasatinib, high-dose imatinib and
nilotinib should be used to treat people with chronic myeloid leukaemia
that has not responded to imatinib or who cannot tolerate imatinib in the
NHS in England and Wales. It explains guidance (advice) from NICE
(the National Institute for Health and Clinical Excellence). It is written for
people with chronic myeloid leukaemia but it may also be useful for their
families or carers or for anyone with an interest in the condition...more
http://www.nice.org.uk/nicemedia/live/13645/57824/57824.pdf
------------------------------------------------------------------------------------------------
Full guidance: TA241
Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance
Issued: January 2012
NICE technology appraisal guidance 241
more......